Table 1.
Current redox clinical investigations for the treatment of neurodegenerative diseases.
| Redox therapy | Clinical application |
|---|---|
| Vitamin E | Alzheimer's disease [20, 21] Parkinson's disease [22, 23] Multiple sclerosis [24, 25] |
|
| |
| Polyphenols | Parkinson's disease [22, 23] Multiple sclerosis [24, 25] Hereditary spastic paraplegia [ClinicalTrials.gov: NCT02314208] |
|
| |
| Coenzyme Q10 | Parkinson's disease [26–29] Multiple sclerosis |
|
| |
| MPAC (i.e., clioquinol) |
Alzheimer's disease [30–32] Parkinson's disease [33, 34] |
|
| |
| ω-3 PUFAs | Multiple sclerosis [35, 36] |
|
| |
| Metalloporphyrins | Amyotrophic lateral sclerosis [37] |
|
| |
| Pramipexole (i.e., KNS-760704) |
Amyotrophic lateral sclerosis [38] |
MPAC: metal protein attenuating compounds; PUFAs: polyunsaturated fatty acids.